A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: A new botulinum neurotoxin A
- 1 June 2012
- journal article
- review article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 18 (5) , 441-445
Abstract
No abstract availableKeywords
Funding Information
- Research to Prevent Blindness
- Merz Pharmaceuticals
This publication has 20 references indexed in Scilit:
- Efficacy and safety of treatment with Incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticityJournal of Rehabilitation Medicine, 2011
- Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—A randomized trialMovement Disorders, 2011
- Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indicationsMovement Disorders, 2010
- Xeomin® in the treatment of cervical dystoniaEuropean Journal of Neurology, 2009
- Routine use of Xeomin® in patients previously treated with Botox®: long term resultsEuropean Journal of Neurology, 2009
- Xeomin®: an innovative new botulinum toxin type AEuropean Journal of Neurology, 2009
- Xeomin is free from complexing proteinsToxicon, 2009
- Xeomin® is stable without refrigeration: Complexing proteins are not required for stability of botulinum neurotoxin type A preparationsToxicon, 2008
- Neurophysiological Double-Blind Trial of a Botulinum Neurotoxin Type A Free of Complexing ProteinsClinical Neuropharmacology, 2007
- Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN??) in Focal DystoniaDrugs, 2007